Investors in Aquestive Therapeutics Face Challenges After Major Price Target Cut Recent price adjustments from Cantor and Oppenheimer raise alarms for investors in Aquestive Therapeutics, signaling potential class action opportunities.

Investors in Aquestive Therapeutics Face Challenges After Major Price Target Cut #United_States #New_York #Securities_Fraud #Aquestive_Therapeutics #Anaphylm

Investors of Aquestive Therapeutics Urged to Review Class Action Lawsuit Updates Robbins LLP alerts shareholders of Aquestive Therapeutics regarding a class action lawsuit over misleading statements regarding drug approval. Investors impacted should seek guidance.

Investors of Aquestive Therapeutics Urged to Review Class Action Lawsuit Updates #United_States #San_Diego #Robbins_LLP #Aquestive_Therapeutics #Anaphylm

FDA Issues CRL for Debutepinephrine Sublingual Film for Anaphylaxis The US FDA has issued a complete response letter for debutepinephrine for the treatment of type 1 allergic reactions including anaphylaxis.

The @fda.gov has issued a complete response letter for #Anaphylm™ (debutepinephrine) for treatment of type 1 allergic reactions, including anaphylaxis, a development of particular interest for patients with #SystemicMastocytosis

Learn more: https://bit.ly/4r2AH0s

#RareDisease #MedSky

Aquestive Therapeutics Announces Positive FDA Feedback and Reaffirms NDA Submission Guidance for Anaphylm™ (epinephrine) Sublingual Film

Read Aquestive's full press release here:
https://buff.ly/3ZkSAuX

#FoodAllergy #FoodAllergies #Allergy #Anaphylaxis #Anaphylm #Epinephrine